Skip to main content
NCD 190.26 · version 1 · Laboratory NCD

NCD 190.26: Carcinoembryonic Antigen

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.26

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
195 covered ICD-10
233 non-covered

TL;DR

NCD 190.26 sets Medicare's national policy for carcinoembryonic antigen under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. CEA may be medically necessary for follow-up of patients with colorectal carcinoma. It would however only be medically necessary at treatment decision-making points. In some clinical situations… As a laboratory NCD it carries a national ICD-10 edit list: 195 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

CEA is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain malignancies to therapy.

Indications and limitations of coverage

Indications

CEA may be medically necessary for follow-up of patients with colorectal carcinoma. It would however only be medically necessary at treatment decision-making points. In some clinical situations (e.g. adenocarcinoma of the lung, small cell carcinoma of the lung, and some gastrointestinal carcinomas) when a more specific marker is not expressed by the tumor, CEA may be a medically necessary alternative marker for monitoring. Preoperative CEA may also be helpful in determining the post-operative adequacy of surgical resection and subsequent medical management. In general, a single tumor marker will suffice in following patients with colorectal carcinoma or other malignancies that express such tumor markers.

In following patients who have had treatment for colorectal carcinoma, ASCO guideline suggests that if resection of liver metastasis would be indicated, it is recommended that post-operative CEA testing be performed every two to three months in patients with initial stage II or stage III disease for at least two years after diagnosis.

For patients with metastatic solid tumors which express CEA, CEA may be measured at the start of the treatment and with subsequent treatment cycles to assess the tumor's response to therapy.

Limitations

Serum CEA determinations are generally not indicated more frequently than once per chemotherapy treatment cycle for patients with metastatic solid tumors which express CEA or every two months post-surgical treatment for patients who have had colorectal carcinoma. However, it may be proper to order the test more frequently in certain situations, for example, when there has been a significant change from prior CEA level or a significant change in patient status which could reflect disease progression or recurrence.

Testing with a diagnosis of an in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.26 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 195 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.26
CodeCode set
82378CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $18.96, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.26 edits, October 2026
CodeCLFS amountWith QWPricing
82378$18.96—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 195 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.26 (sample)
ICD-10-CMDescriptionEffective
C15.3Malignant neoplasm of upper third of esophagus2015-10-01
C15.4Malignant neoplasm of middle third of esophagus2015-10-01
C15.5Malignant neoplasm of lower third of esophagus2015-10-01
C15.8Malignant neoplasm of overlapping sites of esophagus2015-10-01
C15.9Malignant neoplasm of esophagus, unspecified2015-10-01
C16.0Malignant neoplasm of cardia2015-10-01
C16.1Malignant neoplasm of fundus of stomach2015-10-01
C16.2Malignant neoplasm of body of stomach2015-10-01
C16.3Malignant neoplasm of pyloric antrum2015-10-01
C16.4Malignant neoplasm of pylorus2015-10-01
C16.5Malignant neoplasm of lesser curvature of stomach, unspecified2015-10-01
C16.6Malignant neoplasm of greater curvature of stomach, unspecified2015-10-01
C16.8Malignant neoplasm of overlapping sites of stomach2015-10-01
C16.9Malignant neoplasm of stomach, unspecified2015-10-01
C17.0Malignant neoplasm of duodenum2015-10-01
C17.1Malignant neoplasm of jejunum2015-10-01
C17.2Malignant neoplasm of ileum2015-10-01
C17.3Meckel's diverticulum, malignant2015-10-01
C17.8Malignant neoplasm of overlapping sites of small intestine2015-10-01
C17.9Malignant neoplasm of small intestine, unspecified2015-10-01
C18.0Malignant neoplasm of cecum2015-10-01
C18.1Malignant neoplasm of appendix2015-10-01
C18.2Malignant neoplasm of ascending colon2015-10-01
C18.3Malignant neoplasm of hepatic flexure2015-10-01
C18.4Malignant neoplasm of transverse colon2015-10-01
C18.5Malignant neoplasm of splenic flexure2015-10-01
C18.6Malignant neoplasm of descending colon2015-10-01
C18.7Malignant neoplasm of sigmoid colon2015-10-01
C18.8Malignant neoplasm of overlapping sites of colon2015-10-01
C18.9Malignant neoplasm of colon, unspecified2015-10-01
C19Malignant neoplasm of rectosigmoid junction2015-10-01
C20Malignant neoplasm of rectum2015-10-01
C21.0Malignant neoplasm of anus, unspecified2015-10-01
C21.1Malignant neoplasm of anal canal2015-10-01
C21.2Malignant neoplasm of cloacogenic zone2015-10-01
C21.8Malignant neoplasm of overlapping sites of rectum, anus and anal canal2015-10-01
C25.0Malignant neoplasm of head of pancreas2015-10-01
C25.1Malignant neoplasm of body of pancreas2015-10-01
C25.2Malignant neoplasm of tail of pancreas2015-10-01
C25.3Malignant neoplasm of pancreatic duct2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.26 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026. The last change was in January 2026, when CMS added 2 codes.

Codes on this NCD's list by release: October 2025: 426 · January 2026: 428 · October 2026: 428. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.26

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.26

What does NCD 190.26 cover?

CEA may be medically necessary for follow-up of patients with colorectal carcinoma. It would however only be medically necessary at treatment decision-making points. In some clinical situations (e.g. adenocarcinoma of the lung, small cell carcinoma of the lung, and some gastrointestinal carcinomas) when a more specific marker is not expressed by the tumor, CEA may be a medically necessary alternative marker… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.26 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.26?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.26?

The October 2026 laboratory NCD edit list contains 195 ICD-10-CM codes that support carcinoembryonic antigen (for example C15.3 Malignant neoplasm of upper third of esophagus; C15.4 Malignant neoplasm of middle third of esophagus; C15.5 Malignant neoplasm of lower third of esophagus) and 233 codes that deny. The list applies to 82378.

How often does the lab NCD code list for 190.26 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.